Figure 1.

Effect of Serum and Tyrosine Kinase Inhibitors on Ferroptosis. (A) Compounds used in this study that we have previously described (Fedorka et al., 2018; Taylor et al., 2019). (B) NCI H522 cells robustly undergo ferroptosis in the presence of Fetal bovine serum (FBS) but not Bovine Calf Serum (BCS). Cells were plated in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS. Twenty four hours later, the medium was replaced with DMEM containing either 10% FBS or 10% BCS and the cells treated with compound 1 (10 μM) or DMSO (vehicle used to dissolve the compound). (C) Tyrosine kinase inhibitors modulate ferroptosis. NCI H522 cells growing in DMEM+10%FBS were exposed to a panel of receptor tyrosine kinase inhibitors in combination with compound 1. Compounds were used at the following concentrations: LY 2109761 (2 μM), ML 347 (0.2 μM), PD 173074 (5 μM), JNJ 1098409 (0.1 μM), PHA 665752 (1 μM), AG 1296 (10 μM), Mubritinib (10 μM), Erlotinib (10 μM), Oclacitib (1 μM), BMS 536924 (1 μM), Ponatinib (1 μM), NVPACC 789 (1 μM) (B and C) Cell survival was determined 72 hours later by methylene blue staining. Viability = absorbance at 668 nm. Bars= mean, error bars=standard deviation, p-value from student t-test (two tailed, unequal variance).